Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health
- 1Division of Endocrinology, Diabetes and Metabolism Virginia Commonwealth University Richmond Virginia USA
- 2Division of Endocrinology, Diabetes and Metabolism Richmond VAMC Richmond Virginia USA
- 3Department of Endocrinology Joslin Diabetes Center, Beth‐Israel Deaconess Medical Center, Harvard Medical School Boston Massachusetts USA
Abstract
Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an atherogenic lipid profile that accelerates atherosclerosis and vascular dysfunction. While statins remain the cornerstone of lipid‐lowering therapy, their cardiovascular benefits decline in advanced CKD. Combination therapy with ezetimibe and newer agents, including PCSK9 inhibitors and bempedoic acid, has shown further cardiovascular risk reduction in CKD. Emerging therapies targeting alternative pathways may address residual lipid abnormalities not corrected by traditional treatments but require longer‐term outcome data in people with DM and CKD. As the prevalence of both conditions rises, applying multifaceted lipid‐lowering strategies may yield the greatest reduction in cardiovascular events and improve survival among this vulnerable population.
Related
- Development and validation of a novel metabolic-inflammatory health-related nomogram for predicting in-hospital mortality in older patients with type 2 diabetes mellitus combined with cardiovascular disease
- Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease
- Prior Cardiovascular Disease and Incident Diabetic Retinopathy in Newly Diagnosed Type 2 Diabetes Mellitus
- Meeting a Proposed Estimated Glomerular Filtration Rate Slope-Based Criterion for Clinical Remission of Chronic Kidney Disease During Sequential Kidney-Protective Therapy in Type 2 Diabetes Mellitus: A Case Report
- Global burden and future trends of type 2 diabetes mellitus-associated chronic kidney disease: analysis of the Global Burden of Disease Study 2021
BibTeX
@article{forrest2026dyslipidaemia,
title = {{Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health}},
author = {Ann S. Forrest and Priyanka Majety and Stéphanie B. Mayer and Om P. Ganda},
journal = {Diabetes, Obesity \& Metabolism},
year = {2026},
month = aug,
doi = {10.1111/dom.71180},
url = {https://doi.org/10.1111/dom.71180},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health
AU - Ann S. Forrest
AU - Priyanka Majety
AU - Stéphanie B. Mayer
AU - Om P. Ganda
PY - 2026
DA - 2026/08/24
JO - Diabetes, Obesity & Metabolism
DO - 10.1111/dom.71180
UR - https://doi.org/10.1111/dom.71180
AB - Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an atherogenic lipid profile that accelerates atherosclerosis and vascular dysfunction. While statins remain the cornerstone of lipid‐lowering therapy, their cardiovascular benefits decline in advanced CKD. Combination therapy with ezetimibe and newer agents, including PCSK9 inhibitors and bempedoic acid, has shown further cardiovascular risk reduction in CKD. Emerging therapies targeting alternative pathways may address residual lipid abnormalities not corrected by traditional treatments but require longer‐term outcome data in people with DM and CKD. As the prevalence of both conditions rises, applying multifaceted lipid‐lowering strategies may yield the greatest reduction in cardiovascular events and improve survival among this vulnerable population.
SN - 1462-8902
SN - 1463-1326
ER -